Af­ter some painful R&D set­backs, J&J part­ners with Arc­turus on a shot at a hep B cure
 — shares rock­et up

A lit­tle over a month ago, J&J salved the wound left by its de­ci­sion to aban­don a multi­bil­lion-dol­lar late-stage hep C pro­gram by say­ing it was shift­ing its R&D at­ten­tion to find­ing a func­tion­al cure for he­pati­tis B. And this morn­ing it took a step in that di­rec­tion with a tie-up with San Diego-based Arc­turus Ther­a­peu­tics, an RNA com­pa­ny that re­versed its way in­to the pub­lic mar­kets a few weeks ago with a deal to merge with the failed biotech Al­co­bra $AD­HD.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER